Aram Nazareth Demirjian, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreaticoduodenectomy | 4 | 2017 | 509 | 0.810 |
Why?
|
| Pancreatic Fistula | 2 | 2013 | 148 | 0.480 |
Why?
|
| Biliary Fistula | 1 | 2014 | 37 | 0.450 |
Why?
|
| Intestinal Fistula | 1 | 2014 | 142 | 0.420 |
Why?
|
| Digestive System Surgical Procedures | 2 | 2015 | 572 | 0.400 |
Why?
|
| Gallstones | 1 | 2014 | 284 | 0.370 |
Why?
|
| Pancreaticojejunostomy | 1 | 2010 | 26 | 0.360 |
Why?
|
| Intestinal Obstruction | 1 | 2014 | 432 | 0.340 |
Why?
|
| Carcinoma, Hepatocellular | 5 | 2015 | 2297 | 0.310 |
Why?
|
| Pancreatic Ducts | 1 | 2010 | 329 | 0.310 |
Why?
|
| Intestine, Small | 1 | 2014 | 1206 | 0.290 |
Why?
|
| Parathyroid Neoplasms | 1 | 2008 | 242 | 0.280 |
Why?
|
| Liver Neoplasms | 5 | 2015 | 4317 | 0.280 |
Why?
|
| Postoperative Complications | 5 | 2017 | 15633 | 0.240 |
Why?
|
| Cholecystectomy | 3 | 2016 | 406 | 0.240 |
Why?
|
| Neurofibromatosis 1 | 1 | 2008 | 561 | 0.220 |
Why?
|
| Meat | 1 | 2006 | 584 | 0.210 |
Why?
|
| Fishes | 1 | 2006 | 603 | 0.210 |
Why?
|
| Pancreatectomy | 2 | 2017 | 811 | 0.190 |
Why?
|
| Fluid Therapy | 2 | 2015 | 579 | 0.190 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 2 | 2016 | 506 | 0.180 |
Why?
|
| Abdomen | 2 | 2015 | 1128 | 0.160 |
Why?
|
| Carcinoma | 1 | 2008 | 2330 | 0.140 |
Why?
|
| Cholangiography | 1 | 2016 | 181 | 0.130 |
Why?
|
| Cholecystitis, Acute | 1 | 2016 | 75 | 0.130 |
Why?
|
| alpha-Fetoproteins | 2 | 2014 | 223 | 0.120 |
Why?
|
| Isotonic Solutions | 1 | 2015 | 117 | 0.120 |
Why?
|
| Portal Vein | 2 | 2014 | 431 | 0.120 |
Why?
|
| Mesenteric Veins | 1 | 2014 | 86 | 0.120 |
Why?
|
| Consumer Health Information | 1 | 2016 | 215 | 0.110 |
Why?
|
| Pancreatic Neoplasms | 4 | 2016 | 5368 | 0.110 |
Why?
|
| Hepatic Artery | 1 | 2014 | 232 | 0.110 |
Why?
|
| Unnecessary Procedures | 1 | 2016 | 415 | 0.110 |
Why?
|
| Gallbladder Neoplasms | 1 | 2013 | 189 | 0.100 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2012 | 128 | 0.090 |
Why?
|
| Comprehension | 1 | 2016 | 621 | 0.090 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 1 | 2010 | 100 | 0.090 |
Why?
|
| Specialties, Surgical | 1 | 2014 | 389 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2015 | 36426 | 0.080 |
Why?
|
| Specialization | 1 | 2014 | 778 | 0.080 |
Why?
|
| Diet | 1 | 2006 | 8075 | 0.070 |
Why?
|
| Perioperative Care | 1 | 2015 | 1036 | 0.070 |
Why?
|
| Hepatitis B, Chronic | 1 | 2011 | 410 | 0.070 |
Why?
|
| Constriction, Pathologic | 1 | 2010 | 1096 | 0.070 |
Why?
|
| Hydroxamic Acids | 2 | 2006 | 481 | 0.070 |
Why?
|
| Colorectal Neoplasms | 1 | 2006 | 6938 | 0.070 |
Why?
|
| Vascular Surgical Procedures | 1 | 2014 | 1489 | 0.060 |
Why?
|
| Boronic Acids | 2 | 2006 | 915 | 0.060 |
Why?
|
| Internet | 1 | 2016 | 3093 | 0.060 |
Why?
|
| Pyrazines | 2 | 2006 | 1201 | 0.050 |
Why?
|
| Logistic Models | 2 | 2017 | 13255 | 0.050 |
Why?
|
| Hepatitis C, Chronic | 1 | 2011 | 1032 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2016 | 7967 | 0.050 |
Why?
|
| Education, Medical, Graduate | 1 | 2014 | 2373 | 0.050 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2006 | 774 | 0.050 |
Why?
|
| Liver Cirrhosis | 1 | 2011 | 1935 | 0.050 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 12059 | 0.040 |
Why?
|
| Reoperation | 1 | 2010 | 4303 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2014 | 5293 | 0.040 |
Why?
|
| Environment | 1 | 2006 | 1123 | 0.040 |
Why?
|
| Apoptosis | 2 | 2006 | 9491 | 0.040 |
Why?
|
| Incidence | 2 | 2017 | 21355 | 0.040 |
Why?
|
| Humans | 19 | 2017 | 761578 | 0.040 |
Why?
|
| Diabetes Mellitus | 1 | 2017 | 5841 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2014 | 6484 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2005 | 1406 | 0.040 |
Why?
|
| Boston | 1 | 2010 | 9326 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 6346 | 0.030 |
Why?
|
| Female | 10 | 2017 | 392688 | 0.030 |
Why?
|
| Aged | 8 | 2017 | 169308 | 0.030 |
Why?
|
| Organizations, Nonprofit | 1 | 2016 | 105 | 0.030 |
Why?
|
| Retrospective Studies | 5 | 2017 | 80646 | 0.030 |
Why?
|
| Treatment Outcome | 4 | 2016 | 64684 | 0.030 |
Why?
|
| Government | 1 | 2016 | 161 | 0.030 |
Why?
|
| Portacaval Shunt, Surgical | 1 | 2014 | 46 | 0.030 |
Why?
|
| Male | 9 | 2017 | 360841 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2017 | 58983 | 0.030 |
Why?
|
| Fats | 1 | 2015 | 99 | 0.030 |
Why?
|
| CA-19-9 Antigen | 1 | 2014 | 106 | 0.030 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2016 | 232 | 0.030 |
Why?
|
| Prognosis | 2 | 2014 | 29629 | 0.030 |
Why?
|
| bcl-X Protein | 2 | 2006 | 410 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 15266 | 0.030 |
Why?
|
| Ownership | 1 | 2016 | 339 | 0.030 |
Why?
|
| History, 18th Century | 1 | 2014 | 207 | 0.030 |
Why?
|
| Mass Media | 1 | 2016 | 303 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2005 | 4352 | 0.030 |
Why?
|
| Time Factors | 2 | 2014 | 39970 | 0.030 |
Why?
|
| Intraoperative Care | 1 | 2016 | 767 | 0.030 |
Why?
|
| Cardiac Output | 1 | 2015 | 831 | 0.030 |
Why?
|
| Complementary Therapies | 1 | 2016 | 486 | 0.030 |
Why?
|
| United States | 3 | 2016 | 72335 | 0.020 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2012 | 221 | 0.020 |
Why?
|
| Saphenous Vein | 1 | 2014 | 516 | 0.020 |
Why?
|
| History, 19th Century | 1 | 2014 | 720 | 0.020 |
Why?
|
| Drug Synergism | 2 | 2006 | 1757 | 0.020 |
Why?
|
| California | 1 | 2015 | 1430 | 0.020 |
Why?
|
| Blood Loss, Surgical | 1 | 2015 | 638 | 0.020 |
Why?
|
| Resuscitation | 1 | 2015 | 673 | 0.020 |
Why?
|
| Erythrocyte Transfusion | 1 | 2015 | 570 | 0.020 |
Why?
|
| Bilirubin | 1 | 2012 | 436 | 0.020 |
Why?
|
| Comparative Effectiveness Research | 1 | 2015 | 709 | 0.020 |
Why?
|
| Neoplasm Staging | 2 | 2014 | 11120 | 0.020 |
Why?
|
| Cholangiocarcinoma | 1 | 2014 | 552 | 0.020 |
Why?
|
| Monitoring, Intraoperative | 1 | 2015 | 942 | 0.020 |
Why?
|
| Risk Factors | 4 | 2017 | 74212 | 0.020 |
Why?
|
| Proportional Hazards Models | 2 | 2013 | 12463 | 0.020 |
Why?
|
| Information Dissemination | 1 | 2016 | 1126 | 0.020 |
Why?
|
| History, 21st Century | 1 | 2014 | 1567 | 0.020 |
Why?
|
| Anesthesia, General | 1 | 2015 | 1174 | 0.020 |
Why?
|
| Propensity Score | 1 | 2015 | 1913 | 0.020 |
Why?
|
| Europe | 1 | 2014 | 3420 | 0.020 |
Why?
|
| Middle Aged | 6 | 2017 | 220917 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 3597 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 2850 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 2319 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2014 | 2767 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 2759 | 0.020 |
Why?
|
| Fellowships and Scholarships | 1 | 2014 | 1117 | 0.020 |
Why?
|
| Quinones | 1 | 2005 | 78 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2015 | 2220 | 0.010 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2014 | 1428 | 0.010 |
Why?
|
| Benzoquinones | 1 | 2005 | 198 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2015 | 4160 | 0.010 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2006 | 426 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 39107 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2005 | 11742 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2015 | 5247 | 0.010 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2005 | 192 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2006 | 13642 | 0.010 |
Why?
|
| Heart Rate | 1 | 2015 | 4195 | 0.010 |
Why?
|
| Caspases | 1 | 2006 | 879 | 0.010 |
Why?
|
| Lactams, Macrocyclic | 1 | 2005 | 318 | 0.010 |
Why?
|
| Protease Inhibitors | 1 | 2006 | 754 | 0.010 |
Why?
|
| Adult | 3 | 2017 | 221200 | 0.010 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2005 | 424 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2014 | 10090 | 0.010 |
Why?
|
| Laparoscopy | 1 | 2013 | 2036 | 0.010 |
Why?
|
| Length of Stay | 1 | 2015 | 6426 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2006 | 54423 | 0.010 |
Why?
|
| Stroke Volume | 1 | 2015 | 5496 | 0.010 |
Why?
|
| Patient Readmission | 1 | 2015 | 3271 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 8002 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 20569 | 0.010 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2005 | 1136 | 0.010 |
Why?
|
| Survival Rate | 1 | 2013 | 12725 | 0.010 |
Why?
|
| Cell Line, Tumor | 2 | 2006 | 16990 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2014 | 4793 | 0.010 |
Why?
|
| Gene Silencing | 1 | 2005 | 1509 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2005 | 2224 | 0.010 |
Why?
|
| Thrombosis | 1 | 2012 | 2942 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2006 | 2490 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2015 | 22176 | 0.010 |
Why?
|
| Phenotype | 1 | 2014 | 16592 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 7391 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2006 | 3713 | 0.010 |
Why?
|
| Disease Progression | 1 | 2012 | 13510 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2005 | 3701 | 0.010 |
Why?
|
| Animals | 1 | 2006 | 168475 | 0.010 |
Why?
|
| Internship and Residency | 1 | 2014 | 5882 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2005 | 8553 | 0.000 |
Why?
|